Jonsson Comprehensive Cancer Center: Breast Neoplasms trials

The registry lists 41 Breast Neoplasms studies with Jonsson Comprehensive Cancer Center as lead sponsor. 3 are open to participants now and 4 have results posted.

Early Phase 1 3Phase 1 12Phase 2 12Phase 3 2Phase 4 1No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible ParticipantsRecruitingNCT05978128Not applicable
• Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast CancerRecruitingNCT04553770Phase 2
• Brain Health in Breast Cancer SurvivorsRecruitingNCT04297020
• Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing SurgeryCompletedNCT03202472Not applicableResults posted
• Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)TerminatedNCT01029925Phase 2Results posted
• Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast CancerCompletedNCT00068341Phase 2Results posted
• Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu OverexpressionCompletedNCT00033514Phase 1/2Results posted
• Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic CancersActive, not recruitingNCT07118176Phase 1
• MR Correlated Spectroscopic Imaging for Diagnosing Breast CancerCompletedNCT06090630Early Phase 1
• Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung CancerTerminatedNCT04705025Not applicable
• Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer SurvivorsCompletedNCT04290897Phase 2
• Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedTerminatedNCT04185311Phase 1
• Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer TissuesActive, not recruitingNCT04147494Early Phase 1
• Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase InhibitorsCompletedNCT03953157Not applicable
• SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast CancerCompletedNCT03411070Early Phase 1
• Kindness Interventions in Enhancing Well-Being in Breast Cancer SurvivorsCompletedNCT03319342Not applicable
• Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast CancerTerminatedNCT03128619Phase 1
• Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)Status unknownNCT03025139Not applicable
• Project Connect Online: An Internet-based Intervention for Women With Breast CancerCompletedNCT02866994Not applicable
• Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving EverolimusCompletedNCT02015559Phase 2
• Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS MetastasisCompletedNCT01783756Phase 1/2
• Study of Survivorship Care Plans and Outcomes in Underserved Breast Cancer SurvivorsCompletedNCT01627366Not applicable
• A Mindfulness Meditation-Based Intervention for Younger Breast Cancer SurvivorsCompletedNCT01558258Phase 2
• Cognitive Rehabilitation Group Intervention for Breast Cancer SurvivorsCompletedNCT01540955Phase 2
• Breast Cancer Screening InterventionCompletedNCT01525264Not applicable
• Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer PatientsCompletedNCT01051609
• Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy ParticipantsWithdrawnNCT00999557Not applicable
• Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast CancerWithdrawnNCT00706615Phase 1
• T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid TumorsCompletedNCT00433407Not applicable
• Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast CancerTerminatedNCT00427427Phase 2
• Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast CancerTerminatedNCT00112749Phase 2
• Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast CancerCompletedNCT00096057Phase 1
• GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/NeuCompletedNCT00085020Phase 1
• Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination ChemotherapyStatus unknownNCT00066547Phase 1/2
• CP-724,714 in Treating Patients With Metastatic Breast CancerCompletedNCT00055926Phase 1
• Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast CancerCompletedNCT00047255Phase 3
• SU006668 in Treating Patients With Advanced Solid TumorsStatus unknownNCT00024063Phase 1
• Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast CancerCompletedNCT00022386Phase 4
• Cryosurgery in Treating Women With Breast LesionsCompletedNCT00020852Phase 1
• Timing of Menstrual Cycle and Surgery in Treating Premenopausal Women With Stage I, Stage II, or Stage III Breast CancerCompletedNCT00005079Phase 3
• Diet and Estrogen Metabolism in Postmenopausal WomenCompletedNCT00003098Not applicable